H Yki-Järvinen1, R Bergholm, M Leirisalo-Repo. 1. Department of Medicine, Divisions of Diabetes, University of Helsinki, Helsinki, Finland. ykijarvi@helsinki.fi
Abstract
BACKGROUND: Endothelial dysfunction, defined as loss of bioactivity of NO in the vessel wall, is thought to precede atherosclerosis. OBJECTIVE: To determine whether endothelial dysfunction characterises patients with RA and whether these patients have increased inducible nitric oxide synthase (iNOS) dependent NO production in vivo. METHODS: and results: Twenty patients with RA and 33 normal subjects received intrabrachial artery infusions of endothelium dependent (acetylcholine (ACh)) and independent (sodium nitroprusside (SNP)) vasodilators to determine arterial responsiveness to NO. Basal flow and its percentage decrease by NG-monomethyl-L-arginine (L-NMMA), an inhibitor of both iNOS and endothelium dependent NOS (eNOS), was used to determine the contribution of iNOS and eNOS dependent NO to basal flow. Both SNP (p<0.01) and ACh (p<0.05) increased blood flow significantly less in patients with RA than normal subjects. Serum concentrations of TNFalpha were, within the RA group, inversely correlated with blood flow responses to both SNP (r=-0.67, p=0.002) and ACh (r=-0.64, p<0.005). Basal flow was significantly increased in RA and correlated within this group with serum CRP (r=0.48, p<0.05), TNFalpha (r=0.61, p<0.01) concentrations, and ESR (r=0.68, p<0.002). L-NMMA decreased basal flow significantly more (-34+/-2%) in the patients with RA than the normal subjects (-24+/-3%, p<0.02), suggesting in view of the blunted response to ACh, increased iNOS activity. CONCLUSIONS: Patients with RA have a dual abnormality in NO dependent vascular function. Basal blood flow is increased in proportion to inflammatory activity and more inhibited by L-NMMA, suggesting increased iNOS activity, and responsiveness to NO is reduced.
BACKGROUND: Endothelial dysfunction, defined as loss of bioactivity of NO in the vessel wall, is thought to precede atherosclerosis. OBJECTIVE: To determine whether endothelial dysfunction characterises patients with RA and whether these patients have increased inducible nitric oxide synthase (iNOS) dependent NO production in vivo. METHODS: and results: Twenty patients with RA and 33 normal subjects received intrabrachial artery infusions of endothelium dependent (acetylcholine (ACh)) and independent (sodium nitroprusside (SNP)) vasodilators to determine arterial responsiveness to NO. Basal flow and its percentage decrease by NG-monomethyl-L-arginine (L-NMMA), an inhibitor of both iNOS and endothelium dependent NOS (eNOS), was used to determine the contribution of iNOS and eNOS dependent NO to basal flow. Both SNP (p<0.01) and ACh (p<0.05) increased blood flow significantly less in patients with RA than normal subjects. Serum concentrations of TNFalpha were, within the RA group, inversely correlated with blood flow responses to both SNP (r=-0.67, p=0.002) and ACh (r=-0.64, p<0.005). Basal flow was significantly increased in RA and correlated within this group with serum CRP (r=0.48, p<0.05), TNFalpha (r=0.61, p<0.01) concentrations, and ESR (r=0.68, p<0.002). L-NMMA decreased basal flow significantly more (-34+/-2%) in the patients with RA than the normal subjects (-24+/-3%, p<0.02), suggesting in view of the blunted response to ACh, increased iNOS activity. CONCLUSIONS:Patients with RA have a dual abnormality in NO dependent vascular function. Basal blood flow is increased in proportion to inflammatory activity and more inhibited by L-NMMA, suggesting increased iNOS activity, and responsiveness to NO is reduced.
Authors: F Perticone; R Ceravolo; A Pujia; G Ventura; S Iacopino; A Scozzafava; A Ferraro; M Chello; P Mastroroberto; P Verdecchia; G Schillaci Journal: Circulation Date: 2001-07-10 Impact factor: 29.690
Authors: H Sakurai; H Kohsaka; M F Liu; H Higashiyama; Y Hirata; K Kanno; I Saito; N Miyasaka Journal: J Clin Invest Date: 1995-11 Impact factor: 14.808
Authors: I B McInnes; B P Leung; M Field; X Q Wei; F P Huang; R D Sturrock; A Kinninmonth; J Weidner; R Mumford; F Y Liew Journal: J Exp Med Date: 1996-10-01 Impact factor: 14.307
Authors: William Bilsborough; Helen Keen; Andrew Taylor; Gerard J O'Driscoll; Leonard Arnolda; Daniel J Green Journal: Rheumatol Int Date: 2006-06-24 Impact factor: 2.631
Authors: G Palma Zochio Tozzato; E F Taipeiro; M A Spadella; P Marabini Filho; M R de Assis; C P Carlos; A P Girol; A B Chies Journal: Clin Exp Immunol Date: 2015-12-10 Impact factor: 4.330
Authors: Anthony S Zannas; Jennifer L Gordon; Alan L Hinderliter; Susan S Girdler; David R Rubinow Journal: J Clin Endocrinol Metab Date: 2020-10-01 Impact factor: 5.958